Trials / Unknown
UnknownNCT04336696
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 199 (estimated)
- Sponsor
- Bassem Mohamed Sieda · Other Government
- Sex
- All
- Age
- 42 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection. Recurrence Free Survival (RFS) was the main issue of the study and calculated as the time from date of surgery to date of relapse or the most recent follow-up contact that patient was known as relapse-free, Study exclusively studied the outcome and advantage of central neck dissection
Detailed description
informed consent taken, study was a prospective cohort study, with controlled group a retrospectively. patients ablated by total thyroidectomy only who failed to achieve ablation with the first dose of iodine 131I may be dynamically risk stratified as high-risk category and managed aggressively. N0 patients will benefit and ablated by total thyroidectomy and prophylactic central neck dissection, PCND decreases the residual, increase the RFS and patients without residual do not need adjuvant RAI therapy except in high risk group. Histological grading, size of the primary tumour, the extension of PTC, the extent of surgery were found to be a strong predicting factor for recurrence-free survival Locoregional recurrence cases always found more in male patients aged more than 45 years old. Size of the primary tumour and the extent of surgery was a significant factor for RFS,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Total thyroidectomy and central neck dissection |
Timeline
- Start date
- 2016-11-02
- Primary completion
- 2020-04-03
- Completion
- 2020-05-03
- First posted
- 2020-04-07
- Last updated
- 2020-04-07
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04336696. Inclusion in this directory is not an endorsement.